Latest news and articles about Blood Products
Total: 1 articles found
Boya Bio-Pharmaceutical saw its 2025 net profits crash by over 70% due to a massive impairment in its acquired medical aesthetics business and regulatory headwinds in the blood products market. The crisis is compounded by the sudden resignation of its CEO after only nine months, signaling deeper governance and strategic integration issues.
